The Multiple Myeloma Research Foundation (MMRF) helps accelerate the development of next generation multiple myeloma treatments to extend patient’s lives, and lead to a cure. MMRF brings treatment to multiple myeloma patients 60% faster than the average through collaboration with best in class partners in the US and Internationally. In the process, we are changing the way cancer research is conducted. MMRF, a 501(c)(3), is the number one private funder of multiple myeloma research in the United States.
Discoveries, trials, research and more. Sign up for the MMRF newsletter.
Follow Kathy Giusti and the MMRF at PMWC 2016 Read more
The MMRF and "New Weapons in the Fight Against Multiple Myeloma". Read More
"For multiple myeloma community, a November to remember" - Read Article
FDA approves Empliciti, a new immune-stimulating therapy to treat multiple myeloma Learn More
FDA approves Ninlaro (ixazomib), new oral medication to treat multiple myeloma Learn More
FDA approves Darzalex for patients with previously treated multiple myeloma Learn More
Patients as Drivers: A Prescription for the Future Read more
Follow MMRF Founder Kathy Giusti and her family's journey through cancer and DNA sequencing. Read More
Connect with patients, engage with experts, get the information you need! MMRF CoMMunity Gateway
At the MMRF, we’re urgently working to develop treatments to extend your life. We can notify you about clinical trials, connect you to other patients with the same disease characteristics, bring you the latest breaking developments, and more. We’re learning every day. You can too.LEARN MORE
The model we have created for drug discovery and development is revolutionary. It brings multiple myeloma treatments to trial 60% faster than average. It has resulted in 10 multiple myeloma drugs receiving FDA approval in the time it normally takes for one. Through the power of new technology, genomics and immunology, it has extended lives that would have been lost to multiple myeloma yesterday. And it is accelerating all the time. Learn how we are doing it.